--- title: "Onconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving?" type: "News" locale: "en" url: "https://longbridge.com/en/news/286870606.md" description: "Onconetix Inc. (ONCO) shares surged 23.65% to $0.38 in after-hours trading, recovering from an 18.26% decline during the regular session. The company reported operational progress from its subsidiary, Proteomedix AG, and initiated the PRIME Study for a prostate cancer test. Despite a negative earnings per share of $6.71 and a market cap of $3.54 million, ONCO's stock has dropped 99.11% over the past year, currently positioned at its annual low." datetime: "2026-05-19T07:03:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286870606.md) - [en](https://longbridge.com/en/news/286870606.md) - [zh-HK](https://longbridge.com/zh-HK/news/286870606.md) --- # Onconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving? **Onconetix Inc. ( ONCO )** shares soared 23.65% to $0.38 in after-hours trading on Monday. The Ohio-based biotechnology company reversed a steep 18.26% regular session decline, closing the stock at $0.31, according to Benzinga Pro data. ## Clinical Validation On May 13, Onconetix ( ONCO ) reported first-quarter 2026 operational progress from its fully-owned Swiss subsidiary, **Proteomedix AG**, developer of Proclarix, a CE-IVD certified blood test designed to identify clinically significant prostate cancer in combination with prostate-specific antigen (PSA) testing. Prostate cancer is the most commonly diagnosed cancer in men in most countries around the world and places a significant burden on patients and healthcare systems. A National Institutes of Health 2019 report found that in 2018, over 1 million new cases of prostate cancer were reported globally, accounting for 7.1% of all cancers diagnosed in men. According to the company, two new peer-reviewed publications from a Denmark-based clinical study reinforced Proclarix’s ability to reduce unnecessary biopsies and overdiagnosis, outperforming both %fPSA and the european randomized study of screening for prostate cancer risk calculator. Onconetix ( ONCO ) also initiated the PRIME Study, a multi-center U.S. validation trial conducted in collaboration with **Labcorp Holdings Inc****.** The study targets up to 500 participants across diverse ethnic groups and represents a step toward launching a domestic lab-developed test. ## Trading Metrics, Technical Analysis Last week, Onconetix ( ONCO ) reported first quarter data, posting an earnings per share of negative $6.71 and revenue of $21,460. The company has a market capitalization of $3.54 million, a 52-week high of $42.08 and a 52-week low of $0.31. The small-cap stock of the commercial-stage company has dropped 99.11% over the past 12 months. The Relative Strength Index (RSI) of ONCO stands at 26.54. ONCO is currently positioned at its annual low. **Benzinga's Edge Stock Rankings** indicate that ONCO has a negative price trend across all time frames.
_Photo Courtesy: Vintage Tone on Shutterstock.com_ **Disclaimer:** This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. **Read Also: Bakkt (BKKT) Stock Jumps Over 16% After Hours: Here's Why The ICE-Backed Crypto Platform Is Trending Overnight** ### Related Stocks - [ONCO.US](https://longbridge.com/en/quote/ONCO.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [LH.US](https://longbridge.com/en/quote/LH.US.md) - [BKKT.US](https://longbridge.com/en/quote/BKKT.US.md) - [BKKT+.US](https://longbridge.com/en/quote/BKKT+.US.md) ## Related News & Research - [Onconetix Advances Proclarix Clinical Validation and Market Expansion](https://longbridge.com/en/news/286404226.md) - [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md) - [Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026 | PFE Stock News](https://longbridge.com/en/news/286767626.md) - [Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report](https://longbridge.com/en/news/286590889.md) - [Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches | TLX Stock News](https://longbridge.com/en/news/286547990.md)